[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.12.79. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 404
Citations 0
Comment & Response
December 19, 2019

Clinical Benefit of Circulating Tumor DNA Analysis in Early-Stage Breast Cancer

Author Affiliations
  • 1Breast Disease Management Group, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
JAMA Oncol. Published online December 19, 2019. doi:10.1001/jamaoncol.2019.5677

To the Editor The study by Garcia-Murillas and colleagues1 suggests an association of detection of circulating tumor DNA (ctDNA) in patients treated for early-stage breast cancer with a high risk of disease recurrence. The authors conclude that 23 of 29 recurrences (79%) were ctDNA positive and that the mean clinical lead time between detection of ctDNA and relapse was 10.7 months (95% CI, 8.1-19.1 months). Garcia-Murillas et al1 also found an association of detection of ctDNA at diagnosis with relapse-free survival (hazard ratio, 5.8; 95% CI, 1.2-27.1). They have shown that ctDNA levels varied in all breast cancer subtypes and were highest in triple-negative cancers, intermediate in ERBB2-positive cancers, and lowest in the estrogen receptor– and progesterone receptor–positive cancers. The presence of ctDNA during follow-up was associated with a shorter relapse-free period in all subtypes. The study validates the method of analyzing ctDNA by personalized digital polymerase chain reaction, in which the tumor mutations are assessed first and then similar mutations are searched for in the plasma of the patient on follow-up to detect molecular residual disease.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×